Moleculin Biotech
MBRX
13 hedge funds and large institutions have $925K invested in Moleculin Biotech in 2023 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 2 closing their positions.
0.48% less ownership
Funds ownership: 7.7% → 7.22% (-0.48%)
13% less funds holding
Funds holding: 15 → 13 (-2)
100% less capital inflows, than outflows
Capital inflows: $0 | Capital outflows: $73.3K
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Squarepoint
New York
|
-$44.7K |
| 2 |
Sio Capital Management
New York
|
-$16.5K |
| 3 |
Two Sigma Securities
New York
|
-$7.59K |
| 4 |
Renaissance Technologies
New York
|
-$4.13K |
| 5 |
CVA Family Office
Denver,
Colorado
|
-$289 |
MBRX Hedge Fund Activity: Q3 2023 in Review
13 of the 6,316 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q3 2023, worth a combined $925K — down 30% from $1.33M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of MBRX and 0 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 0 added.
The largest seller was Squarepoint, exiting entirely with an estimated $44.7K sold.
- 13 institutional investors held Moleculin Biotech (MBRX) as of Q3 2023, down from 15 in Q2 2023.
- Funds reported $925K of Moleculin Biotech stock for Q3 2023, down 30% quarter-over-quarter.
- 0 funds opened new Moleculin Biotech positions in Q3 2023 and 2 closed out, a net change of -2 holders.
- The largest Moleculin Biotech seller in Q3 2023 was Squarepoint, an estimated $44.7K sold.
Based on aggregated 13F filings for Q3 2023.